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1. Introduction
Liquid chromatography coupled online to mass spectrometry (LC-
MS) is arguably the most widely used bioanalytical technique due to its
sensitivity and selectivity. It is a very versatile analytical approach that
can be tuned to address a wide range of molecules with applications
from environmental analysis to drug analysis and doping control. LC-
MS is increasingly used for the analysis of proteins, typically after a
proteolytic digestion step which converts the macromolecular analytes
into lower-molecular weight peptides, which can be readily quantified.
LC-MS analysis of intact proteins, however, is still in its infancy, being
mainly restricted to the detailed characterization of biopharmaceuticals
in dose formulations [1–10]. The analysis of intact proteins in complex
biological samples, referred to here as protein bioanalysis, has re-
mained the realm of ligand binding assays (LBAs) and notably of en-
zyme-linked immunosorbent assays (ELISAs) due to their exquisite
sensitivity and specificity. A disadvantage of ELISAs is that specificity
can often not be assessed due to a lack of alternative analytical tech-
niques and the fact that the binding site is not known (or not provided
by the manufacturer). Despite considerable advances in mass spectro-
metry and liquid chromatography, protein bioanalysis by LC-MS re-
mains challenging due to the fact that a given (set of) protein(s) needs
to be detected in a sensitive and selective manner in a matrix of
(hundreds of) thousands of other proteins. The task is further compli-
cated by the fact that proteins are not very amenable to LC separation
and that they generate complex mass spectra upon electrospray ioni-
zation (ESI), the most widely used ionization method for protein ana-
lysis by LC-MS, due to multiple charge states (so-called charge-state
envelopes). Quantitative protein bioanalysis, notably in the area of
biopharmaceuticals, would, however, benefit from analysis at the intact
protein rather than at the peptide level, since protein species (also
known as proteoforms) [11–18] should be separated from each other to
facilitate the assignment of modifications to a given species. Despite
these incentives, it is fair to say that protein bioanalysis is currently
dominated by the bottom-up approach using so-called signature or
proteotypic peptides as surrogates for the proteins of interest, since LC-
MS analysis at the protein level is often not sensitive and specific en-
ough.
This review discusses the challenges of quantitative protein bioa-
nalysis by LC-MS at the protein level. We will notably address the
possibilities and current limitations of protein sample preparation, se-
paration by LC, the challenge of interpreting protein ESI-MS spectra and
the options for protein quantification based on extracted ion chroma-
tograms or deconvoluted spectra. The possibilities of high-resolution
mass spectrometry (HRMS) with respect to improving the signal-to-
noise (S/N) ratio and the challenges of analyzing complex mass spectra
will be highlighted based on examples.
2. Sample preparation: a critical step in protein bioanalysis
The bioanalysis, and notably the quantification, of therapeutic
proteins (biopharmaceuticals) and macromolecular biomarkers in
complex biological samples like serum or plasma requires dedicated
sample preparation. Because of the often low concentrations of the
protein analyte and the presence of many endogenous proteins that
easily interfere in the LC-MS analysis, it is essential that the sample
should be cleaned up and the protein(s) of interest enriched [19].
Enrichment strategies for intact proteins are typically based on se-
lectively capturing the protein of interest with an affinity ligand such as
an antibody, receptor or another affinity binder. More generic enrich-
ment techniques, such as solid-phase extraction (SPE) using electro-
static or hydrophobic interactions, immobilized metal affinity columns
(IMAC) or fractionated protein precipitation can also be applied but
they require careful optimization based on the physical-chemical
properties of the target protein to obtain sufficient selectivity [20].
Sample preparation for intact protein analysis by LC-MS, and spe-
cifically affinity-based enrichment, depends on the specificity of the
affinity ligand. Monoclonal-, polyclonal- or engineered recombinant
antibodies as well as biological receptors are widely used as capturing
agents. For each type of ligand, it is important to know against which
part of the protein analyte it is directed and which proteoform of the
protein is captured, to allow proper interpretation of the results. For
https://doi.org/10.1016/j.jchromb.2019.01.032
Received 2 November 2018; Received in revised form 20 January 2019; Accepted 31 January 2019
⁎ Corresponding author.
E-mail address: r.p.h.bischoff@rug.nl (R. Bischoff).
Journal of Chromatography B 1110–1111 (2019) 155–167
Available online 01 February 2019
1570-0232/ © 2019 Elsevier B.V. All rights reserved.
T
example, when using the biological receptor to capture a protein, it
must be considered that only protein species that retain affinity for the
receptor will be enriched, indicating that they still have at least some
biological activity. Any proteoform of the protein that has undergone
enzymatic (e.g. by proteolysis) or chemical modifications (e.g. by oxi-
dation or deamidation) at the site of binding and, as a consequence, has
lost its ability to bind to the receptor, will not be captured and thus
escape analysis.
There is a growing number of affinity binders that are based on
other protein scaffolds. Examples are DARPins, aptamers and affimers.
DARPins (Designed Ankyrin Repeat Proteins) are genetically en-
gineered proteins typically exhibiting highly specific and high-affinity
target protein binding [21]. They are derived from natural ankyrin
proteins, one of the most common classes of binding proteins in nature.
Affimers are affinity binders based on a structurally robust protease
inhibitor scaffold (e.g. Cystatin A) [22,23]. Both types of binders are
selected by phage display against the target protein and produced in an
E. coli protein expression system. DARPins and affimers have a defined
amino acid sequence with defined binding regions that are amenable to
protein engineering (e.g. the insertion of a unique cysteine residue for
immobilization in affimers). Multiple affimers may be used in a single
assay to capture several proteins and to analyze them by LC-MS [24].
If a broad recognition of the different forms of a protein analyte is
desired, it is sometimes advantageous to use polyclonal antibodies that
recognize multiple epitopes. However, this may come at the price of
more unspecific binding. As often is the case with complex analytical
problems, there is no ‘one size fits all’ solution and complementary
strategies may have to be used to get a comprehensive view of the
species that are related to a given protein. An important parameter to
be optimized during method development is the ratio of the carrier (e.g.
the magnetic bead volume) to the amount of capturing affinity binder,
which must be related to the estimated maximum protein concentra-
tion, to determine at which point all binding sites are saturated. Such
‘titration experiments’ prevent inaccurately low results at high analyte
concentrations due to antibody saturation and competition between
protein species for binding. In general, for all types of sample pre-
paration approaches, it is critical to assess and ideally avoid non-spe-
cific binding of proteins to carrier materials to arrive at reproducible
results with good recovery.
Affinity ligands can be coupled to polymer resins, magnetic beads,
immobilized on 96-well enzyme-linked immunosorbent assay (ELISA)
microtiter plates or on monolithic micro-columns. The coupling
chemistry depends on the reactive groups on the carrier and the func-
tional groups on the affinity ligands. It is beyond the scope of this re-
view to cover this field completely, but a few examples will be de-
scribed to delineate the principle. An antibody can, for example, be
biotinylated using an N-hydroxysuccinimide biotin derivative that re-
acts with primary amino groups on lysine residues and the N-termini of
the heavy and light chains. The biotinylated antibody can then be
coupled to a streptavidin-labelled carrier, because of the strong inter-
action between biotin and streptavidin. When using an ELISA plate,
there is a choice between unmodified and a variety of surface-activated
microtiter plates. As in the case of setting up a regular sandwich ELISA
assay, it is necessary to evaluate different types of ELISA plates for the
best recovery and selectivity. There are many examples where affinity-
based sample preparation is used for protein analysis, although en-
richment is typically followed by trypsin digestion and LC-MS analysis
at the peptide level [25]. Kellie et al. described immunocapture to en-
rich a monoclonal antibody (mAb) from human plasma followed by
digestion with IdeS (see later in this section for details about this ap-
proach) and reduction of the disulfide bonds [26]. LC-MS analysis on a
C4 reversed-phase column at 65 °C allowed separation of the Fc/2, LC
and Fd subunits. The LC subunit of the captured antibody was used as
internal standard to correct for losses. The method was quantitative
across the range of 0.5–10 μg/mL based on Extracted Ion Chromato-
grams (EICs) of the 20+ charge state. Other examples of intact protein
bioanalysis are scarce, but many of the ‘peptide-based’ methods might
serve as the basis for intact protein analysis by analyzing the proteins
that are eluted from the capturing agents directly by LC-MS without
prior digestion. Immunoaffinity-MS analysis of intact proteins has also
been shown successfully in conjunction with matrix-assisted laser des-
orption ionization (MALDI) albeit for relatively small proteins [27–29].
Since protein A and protein G show affinity towards the constant
part of human IgG, carriers can be coated with one or a combination of
both proteins in order to immobilize capturing antibodies or to extract
therapeutic mAbs. There are positive and negative aspects of this kind
of sample preparation. Advantageous is that such methods can be ap-
plied to different types of proteins containing IgG-like Fc parts. They are
robust, can be used to capture multiple therapeutic antibodies (or their
protein species) in one analysis and are easy to transfer to 96-well plate
formats. A negative aspect of using protein A and/or G is that they bind
all human IgG molecules, of which there are many in blood serum or
plasma, at a total concentration of 15 mg/mL, so that analysis at the
protein level is generally not possible. In recent years, affinity enrich-
ment has been shifting from manual sample preparation to automated
platforms based on well-plate-, magnetic bead-, cartridge- or tip-based
immunocapture platforms. Automation leads to improved precision,
shorter sample preparation times and more robust methods, because
samples can be processed (captured, washed and eluted) according to
the same protocol and often simultaneously.
The affinity enrichment method described by Berna et al. [30] in-
corporates a sample preparation step using immunoprecipitation (IP)
for quantitative protein analysis by LC-MS. IP was set up in a 96-well
plate format using protein A/G to immobilize the capture antibody. The
authors refer to this technique as immunoprecipitation in ELISA format
or IPE. Proteins were eluted from the antibodies with 5% aqueous
acetic acid, which is MS compatible, so this method could also be used
for intact protein analysis. This approach, with some modifications, was
applied by Klont et al. [31], to enrich the soluble Receptor of Advanced
Glycation End-products (sRAGE), a biomarker that is under investiga-
tion in Chronic Obstructive Pulmonary Disease (COPD), from serum
and to quantify it by LC-MS at the sub-ng/mL level after digestion.
Reversed-phase SPE is commonly used for the enrichment of pro-
teins between 10 and 35 kDa. With relatively small pore sizes of
80–130 Å (8–13 nm), the separation is not only based on hydrophobic
interactions of the proteins with the stationary phase, but also on size-
exclusion effects, which helps remove larger, highly abundant proteins
like albumin or IgGs from serum or plasma, as they cannot penetrate
into the pores. An example of reversed phase SPE for protein enrich-
ment is the quantification of human growth hormone (approx. 22 kDa)
in serum by Pritchard et al. [32]. These authors used a two-step re-
versed phase SPE process at high and low pH for enrichment at the
intact protein level prior to tryptic digestion directly on the C18-based
SPE material. Monolithic SPE phases may be beneficial for protein ex-
traction for several reasons. Monolithic column materials consist of a
single piece of a highly porous structure that is silica- or polymer-based
[33,34]. Due to the high porosity of the material and the large acces-
sible surface area, binding of high-molecular-weight proteins is im-
proved. Yang et al. [35] used monolithic C18 SPE for quantification of
PEGylated interferon alpha-2a (approx. 40 kDa) at the low ng/mL level
in serum. These levels were achieved with LC-MS analysis at the peptide
level, while the monolithic SPE step was performed at the protein level.
The use of IMAC-SPE during sample preparation is rather un-
common for protein enrichment, whereas it is widely used for the en-
richment of phosphorylated peptides. Some proteins have a particularly
high affinity for metal ions, notably for doubly or triply charged tran-
sition metal cations. Surface-exposed histidine residues are known to
exhibit affinity for immobilized Ni2+, a feature that was used by
Wilffert et al. [20] for the enrichment of recombinant human TNF-re-
lated apoptosis-inducing ligand (rhTRAIL) from serum. In analogy to
the enrichment of phosphorylated peptides, IMAC is also used for the
enrichment of proteins containing phosphorylated threonine, serine or
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tyrosine residues, which have a strong affinity for trivalent metal ions
like Fe3+, Ga3+ and Al3+.
When it comes to mAbs, the most widely used class of biopharma-
ceuticals, there is a specific approach for bioanalysis at the protein
domain level after digestion with IdeS (immunoglobulin-degrading
enzyme from Streptococcus pyogenes) [19–21]. IdeS is a cysteine pro-
tease that cleaves at the hinge region of all IgG subclasses. The enzyme
is highly specific and no other substrate besides IgG is known [36,37].
Digestion of IgG with IdeS generates a homogenous pool of F(ab′)2 and
Fc/2 fragments and there is no ‘over-digestion’ or further degradation
of the fragments as is often the case with other proteolytic enzymes.
Since the hinge region of IgG molecules is flexible and solvent-ex-
posed, digestion is fast. Digestion of IgG using IdeS produces two
identical mAb subunits that correspond to the constant region of the
heavy chain and are called Fc/2, plus a larger domain that is referred to
as F(ab′)2. This consists of the two light chains (LC) and the variable
parts of the heavy chains that are interconnected via a number of dis-
ulfide bonds. Treatment with a reducing agent cleaves the disulfide
bonds and converts F(ab′)2 into two light chains and two separate
variable parts of the heavy chain, Fd (Fig. 1). All subunits are ap-
proximately 25 kDa and thus more amenable to LC-MS analysis than the
entire antibody, while still providing most of the molecular context for
structural modifications.
The use of IdeS in the analysis and characterization of IgGs and
fusion proteins at the protein domain level using liquid chromato-
graphy or capillary electrophoresis in combination with high-resolution
mass spectrometry has been described in several reports, albeit pri-
marily for pharmaceutical product control in samples of limited com-
plexity [38–41]. An et al. [42] developed a method for the identifica-
tion and routine monitoring of domain-specific modifications.
Suitability of the methodology was demonstrated for a number of IgG
subclasses (IgG1, IgG2 and IgG4), as well as for an Fc fusion protein.
IdeS digestion was followed by reduction of disulfide bonds and sub-
sequent analysis by LC-MS, capillary isoelectric focusing and glycan
mapping to enable domain-specific profiling of oxidations, charge
heterogeneity, and glycoform distribution. Leblanc et al. [43] used IdeS
to study long-term storage stability of a proprietary mAb at 5 °C. An
aged mAb, stored for nine years at 5 °C and presenting a complex charge
variant profile, was investigated by cation-exchange (CEX)-LC and
high-resolution MS. Mobile phases consisted of 50 mM ammonium
formate buffered with formic acid at pH 3.9 (Buffer A) and 500 mM
ammonium acetate, pH 7.4 (Buffer B), resulting in both a pH and a salt
gradient. Peptide mapping was subsequently used to localize modified
sites and provide quantitative information. Results showed a
remarkable consistency of the data. IdeS digestion has also been im-
plemented for the comparison of originator mAbs and biosimilars. Pi-
supati et al. [44] demonstrated the utility of a ‘multiple-attribute
monitoring’ workflow using Remicade (Infliximab) and its biosimilar
Remsima as models. IdeS digestion was used to determine the intact
masses of the resulting fragments in their fully glycosylated state, after
deglycosylation and/or disulfide bond reduction. They concluded that
the workflow effectively proved that the two antibodies were similar,
yet not identical. Reported differences, related to the levels of charge
variants attributed to C-terminal truncation and dimer formation, were
ultimately deemed non-consequential. Wagner-Rousset et al. [45] de-
scribed the development of a rapid analytical platform to assess charge
variants of mAbs (acidic and basic species). The workflow was based on
comparative analysis by CEX of intact IgGs versus F(ab)′2 and Fc do-
mains generated by IdeS digestion. The analytical procedure was vali-
dated according to FDA and EMA guidelines in analogy to already ap-
proved mAb-based biopharmaceuticals. Functional assays and peptide
mapping were performed to localize the modifications and assess their
effect on biological activity. This approach can be used during the early
stages of research and development of novel biopharmaceuticals to
screen for and select optimized candidates by discriminating between
critical and less critical charge variants, according to the CEX charge
variant profiles of IdeS digested mAbs. This is an important feature
since the identification of ‘hot spots’ is an important part in further
(pre)-clinical development.
3. Protein separation by liquid chromatography
Liquid chromatography (LC) is one of the most powerful separation
techniques and in combination with mass spectrometry is widely used
in the field of bioanalysis. Due to their large size, intricate higher order
structure and heterogeneity, chromatographic separation of proteins is
extremely challenging. While sample preparation is a crucial and in-
dispensable step to achieve sensitivity and selectivity in protein bioa-
nalysis, it would not be possible to address protein heterogeneity to any
appreciable extent without efficient LC separation prior to mass spec-
trometry. In the following, we will highlight some aspects of column
technology as well as operational variables of chromatographic protein
separations related to intact protein bioanalysis. Many aspects were
developed for the characterization of therapeutic proteins and have
only been partially translated to their analysis in complex samples. This
is one of the main challenges lying ahead for protein bioanalysis.
Pioneering work of the groups of Regnier, Hearn and others in the
1980s established that efficient protein separation requires
Fig. 1. Schematic representation of the digestion of an antibody (IgG) with IdeS followed by reduction of disulfide bonds resulting in Fd′, LC (light chain) and Fc/2
fragments of approximately 25 kDa each.
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chromatographic materials with large enough pores to allow access to
the inner pore volume [46–53]. Insufficiently large pores lead to peak
broadening due to slow mass transfer and may result in column fouling
since not all proteins are eluted. A better theoretical understanding of
protein separations by high-performance (HPLC) and later ultra-high-
performance LC (UHPLC) led to the development of novel concepts,
such as silica or polymer monoliths, with large, μm-sized flow-through
pores and mesopores on the order of hundreds of nm allowing for ef-
ficient and rapid protein separation [54–59]. More recent developments
in separation science based on the design and engineering of micro-
pillar-containing columns instead of packed bed or monolithic mate-
rials hold promise that separation media for intact proteins can be
designed based on fundamental chromatographic theory and nanoscale
engineering [60–64]. While advances in protein separation by LC have
been relatively slow over the last decades, we may be entering a new
phase with breakthroughs ahead. As the following examples will show,
such breakthroughs are sorely needed in order to advance LC separation
of proteins to a level that is commensurate with the complexity of in-
dividual proteins such as biopharmaceuticals or biomarkers let alone
with the complexity of entire proteomes. LC separation of intact pro-
teins currently lags behind in separation power of two-dimensional gel
electrophoresis, an approach that was developed in the 1970s, but
which is cumbersome and not suitable for robust, quantitative protein
bioanalysis.
Reversed-phase LC (RPLC) is one of the major analytical techniques
used in the bioanalysis of proteins. RPLC as such is not ideal for protein
analysis since the harsh mobile phase conditions and the elevated hy-
drophobicity of the stationary phase result in denaturation and may
even induce protein precipitation or irreversible protein adsorption
leading to poor recoveries and the loss of certain protein species.
However, the wide range of stationary phases and notably the ease with
which RPLC can be coupled to mass spectrometry counterbalance these
disadvantages. Damen et al. [65] developed one of the first bioanaly-
tical methods for the quantitative determination of intact trastuzumab,
a monoclonal antibody for the treatment of metastatic breast cancer, by
immunoaffinity enrichment followed by HPLC with fluorescence de-
tection mainly based on Trp residues in the protein. Gradient elution
was applied at a flow rate of 0.5 mL/min through a 150 × 2.1 mm ID
column packed with a C8 material with a particle size of 5μm and an
average pore size of 300Å (30nm). The column temperature was 75 °C
and mobile phase A consisted of 0.1% trifluoroacetic acid (TFA) in
water while mobile phase B consisted of 0.1% TFA in a mixture of
isopropanol-acetonitrile-water (70:20:10). Coupling the LC separation
to mass spectrometry resulted in insufficient sensitivity, indicating that
efficient ionization of intact proteins is challenging. The authors sug-
gested two reasons explaining the loss of sensitivity. Firstly, the high
viscosity of the mobile phase as a result of the presence of isopropanol
negatively affected spray performance. Secondly, the presence of TFA
as ion pairing agent in the mobile phase led to ionization suppression.
Thus, the authors decided to discontinue the use of mass spectrometry
and switched to fluorescence detection. To prove the selectivity of the
LC separation, trastuzumab was mixed with other therapeutic mAbs
like adalimumab, bevacizumab, and rituximab. All components of the
mixture were separated well. A number of limitations of this approach
are obvious. First, fluorescence detection does not allow to gather
chemical information from the analytes, such as molecular mass, or
elucidate potential sources of heterogeneity. Second, while more sen-
sitive than mass spectrometry, in this particular case, intrinsic Trp
fluorescence is not very strong resulting in a limit of detection on the
order of 5 μg/mL. While this is sufficient for highly dosed monoclonal
antibodies like trastuzumab, it is insufficient for many other bio-
pharmaceuticals and for most biomarkers. This is also due to the fact
that almost every protein contains Trp, which results in a considerable
background signal (Fig. 2). Mass spectrometry and notably high-re-
solution mass spectrometry allows more specific detection of proteins
based on extracted ion chromatograms (EICs) with narrow mass
extraction windows (MEWs) (see later in this article). However, the
efficient ionization of proteins in their intact form remains a con-
siderable challenge.
Another interesting feature of protein RPLC is that elevated tem-
peratures lead to much improved separations. While this is a general
phenomenon in LC, since the viscosity of the mobile phase decreases
with increasing temperature, it is particularly striking for proteins. In
their study of intact protein bioanalysis by high-resolution full scan
mass spectrometry, Ruan et al. [66] used human lysozyme as a model
protein to evaluate the effect of different column temperatures. While
chromatography at room temperature resulted in a broad peak with
poor peak shape, increasing the column temperature to 70 °C gave a
narrow, symmetrical peak. The fact that different interchanging protein
conformations may result in broad, asymmetric chromatographic peaks
was already studied by Cohen et al. [67] in the 1980s, who reported
that raising the column temperature is important for reducing the
number of protein conformers (most likely by denaturing the protein
into its unfolded state) and hence reducing peak broadening. Elevated
column temperature is thus considered essential for efficient protein
separation and notably for the separation and recovery of hydrophobic
proteins and peptides. It can be concluded that sharp peaks at high
temperatures are due not only to an increase in column efficiency but
also due to reducing the number of conformational states of a given
protein.
An acidic ion-pairing agent is typically added to the mobile phase of
RPLC separations of peptides and proteins to improve chromatographic
performance. TFA, at a concentration of 0.05–0.1% is widely used for
this purpose since its introduction by Bennett et al. in 1977 [68] and
further studies by Pearson et al. [69]. TFA reduces peak broadening and
tailing since it binds to and neutralizes positively-charged amino acids
thereby reducing interactions with silanol groups on the stationary
Fig. 2. Chromatograms of blank serum (A) and trastuzumab-spiked serum at
the LLOQ (5 μg/mL) (B) after immunoaffinity enrichment using anti-trastu-
zumab idiotype antibodies. The retention time of trastuzumab is around
16.8 min (reproduced from Damen et al. 2009 with permission, copyright
Elsevier).
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phase. TFA and its less widely used longer chain analogue hepta-
fluorobutyric acid (HFBA), further improve solubility and strengthen
the interaction with the hydrophobic stationary phase. While less ef-
fective in improving chromatographic separation efficiency, formic acid
(FA) has gained in popularity for LC-MS separations of proteins and
peptides, since TFA suppresses ion formation in the electrospray source.
Jian et al. [70] established a workflow for the absolute quantitation of
large therapeutic proteins in biological samples at the intact level by
LC-HRMS. The authors used FA as a mobile phase additive rather than
TFA, despite the fact that FA gave broader peaks, in favour of max-
imizing signal intensity. Somsen et al. [71] showed recently that the
ionization suppression effect of TFA may be counterbalanced by adding
a dopant gas to the electrospray interface. While this option is not
available in all mass spectrometers, it is of interest to note that LC se-
paration efficiency, which is better with TFA as ion pairing agent, may
not have to be compromised in favour of a strong ESI-MS signal.
In the recent past, wide pore (> 300 Å) core-shell particles have
been developed for the separation of proteins [72,73]. Core-shell par-
ticles, also called superficially porous particles, have a porous shell on
top of a non-porous core resulting in a material with an efficiency that
is comparable to particles of smaller diameter due to the shorter dif-
fusion path length, resulting in fast mass transfer while producing less
backpressure than UHPLC-type particles (1.7–1.8 μm diameter). To-
doroki et al. [74] used a wide-pore core-shell RPLC column at 70 °C for
the separation of purified mAbs as sharp peaks within 20 min. This
approach was developed into a bioanalytical method for the quantifi-
cation of bevacizumab and infliximab in human plasma by a combi-
nation of immunoaffinity enrichment, high-temperature RPLC and
fluorescence detection.
Organic polymer-based monolithic columns emerged as an alter-
native to silica-based stationary phases for rapid and efficient biomo-
lecule separation. A monolith is a cylindrically shaped polymer that
contains a continuous and interconnected network of pores (channels).
The first monolithic stationary phases were based on polymethacrylate
or polystyrene-divinylbenzene in large inner diameter columns [75].
Nowadays, a wide variety of monomers is available for the preparation
of polymer-based monoliths [75–77]. Polymer monoliths are stable at
elevated column temperatures and across a broad pH range.
The porosity of polymers is a macromolecular characteristic that can
be controlled by varying the composition of the polymerization mixture
and the reaction conditions, such as polymerization temperature and
time [77]. Most monolithic columns developed so far feature hydro-
phobic reversed-phase functionalities, because RPLC is generally re-
garded as the most effective separation mode. However, the wide
variety of functional and cross-linking monomers allows the creation of
monoliths carrying the desired surface chemistry to achieve LC se-
parations in different modes. An example is an ion-exchange column
based on a polymer monolith [78].
Monolithic materials are well-suited for the design of miniaturized
columns [75]. The robustness of such columns can be increased via
covalent linkage of the monolith to the inner capillary wall. Lanshoeft
et al. used a 1 mm × 250 mm polymer-based monolithic column to
develop an immunoaffinity enrichment, LC-HRMS workflow for quan-
tification of a hIgG1 at the intact protein level in rat serum [79]. The
column was based on an ethylvinylbenzene-divinylbenzene copolymer
and the column temperature was raised to 70 °C for better separation
and peak resolution.
Recently, Jin et al. reported a method for the quantitation of an
intact antibody-drug conjugate (ADC), trastuzumab emtansine, in rat
plasma [80]. Both trastuzumab and trastuzumab emtansine eluted at
very similar (almost identical) retention times. The broader chroma-
tographic peak for trastuzumab emtansine as compared to trastuzumab
indicated some separation of species with different drug-to-antibody
ratios (DARs). According to mass spectrometric analysis, the authors
observed that lower DAR species eluted first and higher DAR species
later when a shallow gradient was used. Since the attached drug
(maytansinoid) is hydrophobic, the hydrophobicity of trastuzumab
emtansine increases with the number of attached drug molecules re-
sulting in the observed elution order. Determining the average DAR is a
critical quality attribute (CQA) for ADCs and elucidating the distribu-
tion of species with different DARs is important to ensure consistent
quality and notably efficacy of the conjugates. However, for LC-MS
quantitation and DAR distribution studies, chromatographic separation
of different DAR species was not sufficient, so the authors had to rely on
the resolving power of HRMS and the spectral deconvolution software
to distinguish different DAR species.
Size exclusion chromatography (SEC), ion exchange chromato-
graphy (IXC), hydrophobic interaction chromatography (HIC) as well as
hydrophilic interaction chromatography (HILIC) are all used in the
quality control of therapeutic proteins during manufacturing. It would
go beyond the scope of this review to discuss each of them in detail, so
we will only present a few examples. The reader is referred to the cited
literature for further details.
Size exclusion chromatography (SEC) is particularly suitable to
address the question of protein aggregation during manufacturing and
storage [81,82]. While there have been reports that SEC can be coupled
to MS, this is not routine because, unless non-volatile buffer compo-
nents are used, SEC is not compatible with online coupling to MS. It is,
however, possible to collect fractions, desalt the proteins and analyze
them by MS. Both anion- and cation-exchange chromatography (IEX)
are widely used for the purification as well as for the analysis of pro-
teins. IEX is particularly suitable for charge-variants, notably due to
deamidation [83,84] and has been coupled online to MS for the char-
acterization of therapeutic proteins [85]. Hydrophilic interaction
chromatography (HILIC) operates on the basis of hydrophilic interac-
tions between the analytes and the stationary phase, which is more
hydrophilic than the mobile phase. An inverse gradient of organic
solvent is used for elution, which makes HILIC highly complementary to
RPLC. Recent work by Somsen et al. [71] showed that HILIC can be
coupled online to MS and that different glycoforms of intact proteins
can be efficiently separated in this way. Hydrophobic interaction
chromatography (HIC) is primarily used as a preparative chromato-
graphic method to purify proteins under native conditions [86]. How-
ever, HIC in conjunction with volatile buffer and salt components has
recently also been coupled to MS [87]. Whether this will develop into a
widely used, robust approach remains to be seen.
The field of high-resolution protein separation by chromatography
has not advanced as much as that of high-resolution mass spectrometry,
since its inception in the 1980s. This has greatly hampered our current
understanding of protein heterogeneity and its implications for protein
function. While the challenges are immense and possibly bigger than in
the field of MS, it is good to see that the growing field of biopharma-
ceuticals has revived this area of research and that fundamentally new
approaches, such as nanoengineered chromatographic columns, are
being developed to advance the field [88].
4. Protein mass spectrometry
Mass spectrometers, especially the widely used triple quadrupole
instruments, initially focused on the analysis of small molecules. More
recent developments and advances in the field of HRMS have opened
new possibilities in the field of protein analysis. Most commonly used
HRMS-systems are based on quadrupole time-of-flight (QTOF) and
Orbitrap mass analyzers combined with ‘soft ionization’ modes like
electrospray ionization (ESI) and matrix-assisted laser desorption ioni-
zation (MALDI). While ionizing large macromolecules is a challenge in
itself, it is further difficult to steer heavy ions through the mass ana-
lyzers and the ion optics to the detector resulting in low ion transmis-
sion when compared to small molecules and peptides. Advances in
hardware and operating conditions (e.g. residual pressures in different
sections of the instrument) have improved the capability of QTOF and
Orbitrap MS systems to handle higher masses enabling the analysis of
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intact antibodies and even viruses. The coupling of ion mobility with
mass spectrometry has allowed the separation of ions on the basis of
charge and shape inside the mass spectrometer adding another di-
mension to HRMS systems.
ESI and MALDI can generate intact gas-phase molecular ions from
hundreds to millions of Daltons. MALDI relies on ion generation upon
irradiation of a light-absorbing matrix in which the proteins are em-
bedded. While the mechanism for ion formation is still not fully un-
derstood, the process entails evaporation and activation of the matrix
by a laser, generating a plume of hot gas containing ionized matrix ions,
which in turn ionize the proteins. MALDI mass spectra of proteins
predominantly show singly-charged ions and, to a lesser extent, doubly
and triply charged ions. This low degree of charge distribution has the
advantage of producing less complicated mass spectra compared to ESI,
which makes interpretation easier. MALDI is, however, prone to ion
suppression and cannot be easily coupled to LC. It is also difficult to
combine MALDI of high-molecular weight molecules with commonly
used mass analyzers like ion traps, triple quadrupoles or orbitraps, since
ions of increasing mass carrying only a single charge are very difficult
to trap efficiently in the quadrupole or orbitrap field regions.
ESI is based on an electrical potential that is applied to the ESI-
needle in the source of the MS. This causes a build-up of positive or
negative ions, depending on the ionization mode (positive or negative),
at the tip of the needle [89–91] leading to the production of charged
droplets carrying the proteins. While the droplets evaporate under
elevated temperature, the ions inside the decreasing volume of the
droplet cause electrostatic repulsion leading to droplet fission, ulti-
mately yielding gas-phase ions. ESI produces mass spectra with multiple
charge states, varying from a few to tens of charges per ion, giving a so-
called charge state envelope. The width of the envelope is influenced by
the state (unfolded/partially folded or folded) of the protein in the li-
quid phase as well as by the energy the ions receive in the interface of
the ESI source. Folded proteins are more compact and the interior
amino acids are less prone to be charged than amino acids at the surface
of the protein. Thus unfolded proteins tend to have broader charge state
envelopes with a higher average number of charges [92]. A wide en-
velope has the disadvantage that the intensity of the signal is dispersed
over many charge states, leading to a loss of sensitivity. In addition,
each molecular ion in the envelope is divided into species with a dif-
ferent mass due to the occurrence of natural heavy isotopes such as 13C,
the so-called isotopologues. The signal for large proteins with many
isotopologues is thus spread out over even more ions, leading to a
further loss in sensitivity. With increasing number of charges, the iso-
topologue peaks within one charge state will be spaced ever more
closely ultimately merging into a single peak whose width is de-
termined by the isotopologue cluster. The charge state envelope can be
modified by adding chemicals [93], so-called superchargers, to the LC-
flow (e.g. post-column) [94] or to the gas-phase of the ESI source [95].
While these chemicals were first used in the field of peptide analysis
[96], they have also been applied for intact protein analysis
[93–95,97,98]. Super-charging shifts the charge state envelope to
higher charge values, thus lowering the m/z ratios. This improves ion
transmission and brings the m/z values within the range of most com-
monly used mass analyzers (notably quadrupoles). Reducing the width
of the charge state envelope may also increase sensitivity by collecting
more ions per charge state resulting in an increase in peak intensity.
Fig. 3 shows the shift in the charge state envelope of recombinant
human growth hormone (rhGH) upon addition of metani-
trobenzylalcohol (NBA), a supercharging agent, to the mobile phase
after the chromatographic separation. In the lower trace (magenta) of
Fig. 3 it is noticeable that the sensitivity of rhGH is increased besides
shifts in the charge state envelope. However, this is also the case for the
background and signals arising from possible co-eluting adducts
(Na + and K+). There should thus be a thorough investigation of the
effect of supercharging on the S/N ratio, especially near the lower limit
of quantification.
The field of super-charging is still in its infancy and it remains to be
seen whether other additives or other means of doping the electrospray
to increase the average charge state and to reduce the width of the
charge state envelope will lead to more sensitive and possibly more
selective detection of intact proteins upon LC-MS. An attractive option
was recently shown by Somsen et al. [71], who doped the gas phase in
the ion source rather than the mobile phase of the LC separation. While
the main goal of these authors was to reduce the ionization suppressive
effect of TFA, they also observed that adding 1% propanoic acid to the
drying gas increased the charge state and reduced the number of TFA
adducts. This approach merits further study, since it allows to affect the
charge state envelope without interfering with the chromatographic
separation.
Another way of reducing the width of the charge state envelope is to
use so-called ‘native mass spectrometry’, meaning mass spectrometry
under conditions that do not denature proteins or that denature them
only partially [99–101]. As the protein maintains (part of) its 3-di-
mensional structure, it acquires fewer charges through protonation or
the association with other cations. This facilitates the resolution of
proteoforms in the m/z domain in contrast to supercharging, which puts
more demands on the resolution of the mass analyzer. However, native
mass spectrometry places considerable constraints on the mobile phase
conditions for the LC separation, the instrumental set-up and the con-
ditions for effective ion transmission (e.g. potentials and residual
pressures). LC-MS under ‘native’ conditions is thus currently not as
sensitive as LC-MS under denaturing conditions. Considering that effi-
cient protein separation by LC requires elevated temperatures, com-
plicates the application of native MS to the bioanalysis of proteins and
notably protein species. Native mass spectrometry is thus mainly used
for product characterization when a large amount of purified ther-
apeutic protein is available for analysis [43,102–107]. Since most
proteins (e.g. mAbs) acquire their specificity due to a well-defined 3-
dimensional structure [108], it is conceivable that native LC-MS may
also be used to distinguish biologically active forms of a protein from
inactive forms (e.g. when combined with the results of activity assays).
This makes native LC-MS a subject that is worth exploring further for
the bioanalysis of protein species and more generally to investigate
protein-protein and protein-small molecule interactions.
Recently the use of ion mobility spectrometry (IMS) has entered the
field of protein analysis [104,106,109–111]. An IMS cell is generally
placed between the ion source and the first quadrupole. IMS may be
described as ‘gas-phase electrophoresis’ and introduces an extra se-
paration dimension after the LC separation and ahead of the actual
mass analyzer. Separation is based on the physical characteristics of
proteins such as lipophilicity, shape and charge [112]. The mobility of
ions along the IMS cell is based on the number of interactions with the
neutral gas under the influence of a potential gradient, which slows the
ions down. Within a single charge state, folded proteins drift faster than
unfolded proteins because they experience fewer interactions with the
buffer gas, and thus have a smaller collisional cross-section. The most
widely used types of IMS cells are drift tubes, the field asymmetric wave
ion mobility cell [113] and the traveling wave IMS (T-Wave). In the
first technique, the proteins move in the drift tube under the influence
of a constant electrical field, while the second technique uses electric
fields modulated by radio frequencies that are produced by coils. T-
Wave IMS utilizes non-uniform, moving electric field/voltage pulses to
push ions through a neutral buffer gas. Species with high mobility
(lower collisional cross-section) surf more on the wave front and are
overtaken by the wave less often than species of low mobility (higher
collisional cross-section). At present, IMS is predominantly used for
biopharmaceutical product characterization and to evaluate disulfide
bond heterogeneity, conjugation heterogeneity (e.g. in ADCs), analysis
of protein aggregation and global conformational changes [114–120]. It
must be noted that gas phase conformations (evaluated by IMS) may be
related, but are not identical to solution-phase conformations. A topic
that requires further investigation and which is of utmost interest for
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the field of ‘native’ mass spectrometry. Another caveat of IMS is cur-
rently that it decreases ion transmission and thus sensitivity con-
siderably, which may be one reason why it is not commonly used.
5. Processing and analysis of intact protein LC-MS data
LC-MS analyses of intact proteins produce complex raw data con-
sisting of retention times, peak heights or areas and m/z ratios. Since
most proteins do not exist as single molecular entities, each protein
species gives rise to a slightly different charge state envelope. The fact
that many protein species are not chromatographically resolved results
in overlapping charge state envelopes, each with their isotopologue
distribution. To complicate matters further, proteins often form non-
covalent adducts with cations such as Na+ or K+, which adds to the
complexity of the resulting ESI-MS spectra. Together, this makes con-
version of the information provided in the ESI-MS raw data into simple
readouts, such as the amount or concentration of a given protein species
or its molecular mass, rather difficult. Examples of the mass spectro-
metric output for proteins of increasing molecular mass are shown in
Fig. 4.
For a relatively small protein such as IGF-1 (molecular mass of
7.5 kDa, Fig. 4A), the number of charge states is limited to just a few. As
mass increases, proteins acquire more and more charges (Fig. 4B and C)
so that for a complete mAb such as trastuzumab (mass of around
145 kDa, Fig. 4D), > 40 different charge states can be formed during
ESI, with the number of charges varying from around 30 to over 70.
Fig. 4 also shows that for smaller proteins the isotopologues of a given
charge state can be resolved in a TOF mass analyzer with a resolution of
30,000. For proteins with masses of > 25 kDa, the resolution of this
mass analyzer is insufficient to resolve the isotopologues and a mass
spectrometer with a considerably higher resolution would be needed
for a complete separation of their signals.
Typically, for each data point in a chromatogram a full mass spec-
trum is acquired, containing the response of all ions corresponding to
the various charge states of a protein that elutes at the particular re-
tention time. An EIC is then constructed by defining a small MEW
around the m/z value that corresponds to the ion of interest. As an
example, Fig. 5 shows an EIC of the 20+ charge state of the Fc/2
fragment and the 44+ charge state of the F(ab′)2 of 1 μg/mL of tras-
tuzumab, after immunoaffinity enrichment from human plasma and
IdeS digestion.
Increasing the width of the MEW may be beneficial, as a larger
number of analyte ions will be detected, and the sensitivity therefore
improved. At the same time, it may also result in the co-extraction of
ions from interfering matrix proteins that elute at the same time and
have an m/z value close to the protein of interest [121]. Alternatively, it
is possible to select only one of the most abundant charge state ions for
quantification and to optimize the width of the EIC extraction window
in order to reach an optimal S/N ratio. Ruan et al. [66] showed that by
selecting the most abundant charge state of lysozyme, it is possible to
improve the S/N ratio from 12 to 40 upon reducing the MEW from
0.5m/z to 10 ppm.
Fig. 6 shows the effect of decreasing the MEW from 1.0 Da (entire
15+ charge state) to 0.25 Da and ultimately to 0.0625 Da (1 isotope of
the 15+ charge state isotope cluster) for the 15+ charge state of re-
combinant human growth hormone (rhGH) after enrichment from rat
plasma. The results show that decreasing the EIC extraction window
does not lead to significant improvements in S/N ratio in this case and
while the absolute signal intensity decreases, the selectivity increases
due to less interference. It has to be noted, that adjusting the EIC ex-
traction window may improve the S/N ratio in other cases depending
on the nature of the background.
Simplifying protein ESI-MS spectra based on the deconvolution of
each charge state envelope into a single peak giving the average mo-
lecular mass of the protein (or protein species) is an attractive ap-
proach. The mathematical process of converting the measured m/z
values into molecular masses starts with assigning a charge state to a
given ion. This can be achieved based on the knowledge (assumption)
that two neighbouring peaks from the same protein molecule are se-
parated by a single charge and that this charge is due to the attachment
of a hydrogen cation (also called a ‘proton’ or simply an H+ ion). If this
assumption is correct, one can use simple algebra to define the charge
state of a given protein ion in a charge state envelope (see Box 1).
To calculate molecular masses from charge state envelopes, algo-
rithms based on different principles have been developed. The so-called
‘Maximum Entropy (MaxEnt)’-based approach, which forms the basis of
Fig. 3. Shift of the charge state envelope for recombinant human growth hormone (rhGH) to higher z values upon addition of metanitrobenzylalcohol (NBA) to the
mobile phase after the chromatographic separation. Upper trace (blue); no addition of NBA; Lower trace (magenta); with post-column addition of 0.16% (v/v) of
NBA. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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most commercially available software packages, tries to take peak
broadening effects, due to unresolved isotopes and limited resolution of
the mass analyzer, into account thereby improving the original quality
of the spectrum (higher resolution and reduction in noise). The MaxEnt
program, as developed by Skilling et al. [122], processes different in
silico generated trial spectra and compares them to the observed
spectrum. Once a predefined level of convergence has been reached,
trial spectra that agree with the original data compose the final prob-
ability distribution of spectra in m/z scale. The spectrum with the
highest entropy, the MaxEnt spectrum, is chosen as the most probable
representation of the original data. The width of the probability dis-
tribution reflects the uncertainty of the MaxEnt result, which is









































Fig. 4. Charge state envelope of IGF-1 (A), recombinant human growth hormone (B), the F(ab′)2 part of trastuzumab (C) and trastuzumab (D) with a zoom into one
charge state, as indicated in the figure (data acquired with a QTOF mass spectrometer at a resolution of approx. 35,000 at m/z 900). While the isotopologue cluster of
IGF-1 is still resolved, this is no longer the case for the larger proteins. The zoom spectra indicate the presence of different protein species.
Fig. 5. LC-MS chromatograms (EICs) of 1 μg/mL trastuzumab in rat plasma, after immunoaffinity enrichment using the HER2-receptor as capturing agent and IdeS
digestion. (A) the 20+ charge state of the Fc/2 fragment (2.63 min) and (B) the 44+ charge state of the F(ab′)2 fragment (3.09 min). Separation was by reversed-phase
LC on a C4 column at 80 °C and detection on a QTOF mass spectrometer at resolution 30,000. The MEW used was 0.5m/z units.
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presented in form of error bars. Since peaks in an ESI-MS charge state
envelope are intrinsically connected (see Box 1), this criterion is used to
qualify the MaxEnt spectrum, as it must explain the entire charge state
envelope above a pre-defined threshold across the selected m/z range.
However, the MaxEnt algorithm does not need to assign a specific
charge state to a given peak to start with. It rather uses all of the in-
formation to connect ‘peaks that belong together’. It is noteworthy to
mention that considerable improvements in mass accuracy and re-
solution of modern mass analyzers facilitate accurate deconvolution of
ESI-MS spectra even for large biopharmaceuticals, such as monoclonal
antibodies [70]. However, they do not take all of the caveats away. That
is why further developments in both mass spectrometry (e.g. reducing
the number of charges per protein ion by ‘native’ mass spectrometry)
and algorithms are ongoing [99].
Fig. 7 shows the results of deconvoluting the charge state envelope
of the Fc/2 subunit of trastuzumab using a maximum-entropy-based
algorithm. While the deconvoluted mass (25,231.6) of the left major
peak corresponds closely to the expected mass of 25,232.0 Da of one
glycoform of trastuzumab (Fc/2 G0F) with the loss of a Lys residue from
the C-terminus, there are other smaller signals that indicate additional
protein species or non-covalent adducts (see insert). It is currently still
under investigation whether this kind of transformation results in valid
quantitative data [70].
While deconvolution makes subsequent data analysis and
Fig. 6. LC-MS chromatograms (HRMS) of 10.0 ng/mL of recombinant human growth hormone after immunoaffinity enrichment from rat plasma. EICs for the 15+
charge state were recorded with an MEW of 1.0 Da (A), 0.25 Da (B) or 0.0625 Da (C).
Box 1
Example of a calculation to derive the molecular mass of the Fc/2 fragment of trastuzumab (after IdeS digestion).
Figs. 4 and 7 shows the ESI spectrum of the Fc/2 part of trastuzumab. To determine the charge state of the ion at 1262.5632 (P1) of the
charge state envelope of the Fc/2 part of trastuzumab, we consider that the following peak at 1328.9577 (P2) has one H+ less and that
z1 − z2 = 1. The mass difference between the two protein ions is thus 1.00794 amu (atomic mass units), the mass of an H+ ion. This
knowledge allows us to calculate the charge state of P1 and from thereon to derive all other charge states based on the assumption that each
consecutive peak towards increasing m/z values in the spectrum is due to the loss of one H+ ion.
From the measured data we derive:
P1 =m/z1 = 1262.5632 and P2 =m/z2 = 1328.9577
From the assumption that each charge state is due to a difference in one H+ ion, we derive:
z1 − z2 = 1 or z1 = z2 + 1
Thus: m = M − z ∙ H+; with m being the molecular mass of the protein and M the molecular mass of the respective molecular ion of
charge state z.
Referring back to the measured values P1 and P2 results in:
P1 = M − z1 ∙ H+ / z1 or P1 = M − (z2 + 1) ∙ H+ / z2 + 1 and P2 = M − z2 ∙ H+ / z2
Resolving these equations with respect to M gives:
P1 ∙ z1 + z1 ∙ H+ = M and P2 ∙ z2 + z2 ∙ H+ = M
Which can be rearranged to:
P1 ∙ z1 + z1 ∙ H+ = P2 ∙ z2 + z2 ∙ H+ or P1 ∙ z1 + z1 ∙ H+ = P2 ∙ (z1−1) + (z1−1) ∙ H+
Resolving the equation on the right with respect to z1 gives:
z1 = −(H+ + P2) / P1 − P2
This allows to calculate the number of charges z1 based on the measured values of P1 and P2.
Inserting the measured values and using the known mass of the H+ ion of 1.00794 gives:
z1 = −(1.00794 + 1328.9577) / 1262.5632–1328.9577 = 20.03, which is close to z1 = 20, as charge states can only acquire integer
values.
With z1=20, we can now calculate the approximate molecular mass of the Fc/2 fragment of trastuzumab as:
M + 20 ∙ H+ / 20 = 1262.5632 or M = 1262.5632 ∙ 20–20 or M=25,231.26 Da
The same calculation for z2 = 19 gives:
M + 19 ∙ H+ / 19 = 1328.9577 or M = 1328.9577 ∙ 19–19 or M=25,231.20 Da
Both values are quite consistent and correspond closely to the expected mass of 25,232.0 Da. By going through the entire charge state
envelope in this manner (using a computer algorithm), we get a list of calculated molecular masses that differ slightly from each other
giving an average value with an estimate of the measurement error.
P. Bults, et al. Journal of Chromatography B 1110–1111 (2019) 155–167
163
quantification considerably easier, it is prone to artefacts. Mathematical
deconvolution algorithms may introduce bias and errors and may not
give an accurate reflection of the intensity of the original signals. The
result of such a deconvolution process depends further on the chosen
parameters such as peak width, signal threshold and the chosen m/z
range. Deconvolution of charge state envelopes from ESI-MS spectra of
different protein species requires their chromatographic separation or,
if this cannot be achieved, sufficient resolution of the mass analyzer to
resolve the charge state envelopes in order for the algorithm to assign
different deconvoluted signals to each form. The occurrence of non-
covalent adducts (e.g. Na+ or K+), which is quite common in protein
ESI-MS spectra, as well as modifications resulting in small mass dif-
ferences (e.g. due to deamidations) may confound the deconvolution
algorithm leading to artefacts with incorrect mass and peak heights or
areas. The use of deconvolution algorithms in regulated, quantitative
bioanalysis thus represents a considerable challenge.
6. Conclusions and future outlook
The analysis of intact proteins by LC-MS receives considerable in-
terest from industry and academia alike. After initial breakthroughs in
the 1980s due to improved chromatography materials (e.g. wide-pore
silica beads) and due to a better understanding of the chromatographic
separation of macromolecules from a theoretical point of view, there
were many years of little progress in this field. The emergence of re-
combinant proteins as therapeutic drugs and their increasing relevance
from a medical as well as from a commercial point of view, has created
renewed interest and led to improvements of protein separations by LC
(e.g. based on core-shell particles and monoliths) in conjunction with
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Fig. 7. Deconvolution of the charge states 20+ and 19+ of the Fc/2 fragments [A] of trastuzumab after IdeS digestion using a maximum entropy-based algorithm [B]
integrated into proprietary software (SCIEX).
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mass spectrometry. Ongoing development of HRMS-systems and new
affinity agents will aid in studying in vivo protein biotransformation in
greater detail possibly leading to a better understanding of how this
affects therapeutic efficacy.
Efficient separation of proteins by (U)HPLC has turned out to be a
much more difficult task than initially anticipated. The low diffusion
coefficient of proteins results in slow mass transfer kinetics and the
possibility to assume multiple interchanging conformations has ren-
dered efficient chromatographic separations more challenging than for
peptides. New developments in the field, for example, the emergence of
columns containing nanoengineered micropillars, hold promise of im-
proving analytical protein separations, but we must remember that the
fundamental physical properties of proteins cannot be changed. They
will define the limits of protein separations by liquid chromatography.
In this review, we have given an overview of the area of intact
protein (bio)analysis by LC-MS starting with the challenges of sample
preparation and ending with the deconvolution of highly complex mass
spectra after electrospray ionization. We notably focused on the LC-MS
analysis of intact proteins in biological matrices, an area that is in its
infancy but that is instrumental for the further development of ther-
apeutic proteins, for the detailed characterization of biomarkers and for
biological and biomedical research in general. While there is still a long
way to go until LC can rival two-dimensional gel electrophoresis with
respect to intact protein separation, the payback for advances in this
area will be large, since protein heterogeneity, for example due to post-
translational modifications, is inherent to the way how nature mod-
ulates the biological activity of proteins and of biological systems in
general. We will not be able to understand this in sufficient detail unless
we develop the necessary bioanalytical tools.
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